The 1988 UK Copyright Designs and Patents Act (CPDA) introduced a provision in Section 52 to restrict the term of copyright protection for artistic works which were exploited by an industrial process. The intention was to bring the term for protection available to industrially produced articles to 25 years, the same as was available under […]
Insights: August 2016
Earlier this year, the Tokyo District Court provided useful comment on the circumstances in which a patent with an extended term may be enforced against products equivalent to the product for which the extended term of protection was granted. The Japanese Patent Act allows for extension of the patent term beyond the usual 20 years […]
In a recent judgment, the High Court of England and Wales has provided clarity on the interpretation of numerical ranges in patent claims and the de minimis principle in relation to threatened infringement. The full judgment of Napp Pharmaceutical Holdings v Dr Reddy’s Laboratories & Sandoz  EWHC 1517 (Pat) can be found here. Since […]
In recent years, the European Patent Office (EPO) has been making a renewed and concerted effort to tackle its backlogs of both pending applications and post-grant proceedings (i.e. oppositions and any corresponding appeals). The latest tactics look to reduce the number of pending applications, by financially encouraging the withdrawal of applications at an early stage, […]
After dominating the track cycling at the Beijing Olympics in 2008 and in London in 2012, expectations were high for Great Britain’s cyclists well before the start of the 2016 Summer Olympics in Rio de Janeiro. With a haul of four gold medals and three silvers from seven track events at the time of writing, […]
Recent advances have led to the ability to activate the immune system against cancer cells. This approach, termed cancer immunotherapy, has shown success with melanoma, leukaemia, and lymphoma, and has great potential for treatment of a wider range of cancers. Another approach attacks multiple pathways fundamental in cancer development, using combinations of therapeutic agents to […]
Enter your email address here to receive our monthly bulletin of IP news and developments.